{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-26-000003","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.397853+00:00","generated_at":"2026-05-16T10:51:47.937469+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nurix outlines bexobrutideg pivotal CLL plan, 83% ORR, $664M cash at JPM","bullets":["Phase 2 DAYBreak CLL-201 enrolled Oct 2025; confirmatory Phase 3 vs pirtobrutinib planned in 2026.","83% ORR and 22.1-month median PFS in r/r CLL with median 4 prior lines; 600 mg dose aligned with regulators.","New tablet formulation for autoimmune; IND target 2026. Partnered IRAK4 (GS-6791, Phase 1) and STAT6 (IND-enabling).","NX-1607 Phase 1a showed immune activation; confirmed partial response in MSS CRC across 82 patients.","Pro forma cash $663.8M after $250M equity raise; added CCO and two new board members."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-26-000003","json":"https://secwatch.observer/filing/0001549595-26-000003.json","markdown":"https://secwatch.observer/filing/0001549595-26-000003.md","text":"https://secwatch.observer/filing/0001549595-26-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000003/0001549595-26-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000003/nrix-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:51:47.937469+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}